Working… Menu

Dropless™ vs. Less Drops™ Pharmaceutical Regimens After Cataract Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02819908
Recruitment Status : Completed
First Posted : June 30, 2016
Last Update Posted : June 30, 2016
Information provided by (Responsible Party):
Bret L. Fisher, M.D., Eye Center of North Florida

Brief Summary:

To compare the relative effectiveness of the Imprimis Dropless™ (TriMoxiVanc) intraocular solution with the Less Drops™ topical formulation of PredMoxiKeterolac (given for the first week post op) followed by PredKeterolac (given for weeks 2 to 4 after surgery).

The hypothesis is that the "dropless" regimen will be non-inferior to the "less drops" regimen in terms of post-operative IOP changes, post-operative healing, and visual quality.

Condition or disease Intervention/treatment Phase
Intraocular Lens Associated Postoperative Inflammation Drug: Imprimis Dropless Drug: Imprimis Less Drops Phase 4

Detailed Description:

Modern cataract surgery has become a relatively short out-patient procedure with small incisions and short post-operative recovery time. Surgery can be influenced by surgical technique and experience. Prophylactic pharmaceutical regimens are designed to control post-operative pain and to reduce the potential for inflammation (i.e. macular edema, CME) and infection (i.e. endophthalmitis).

The most serious potential infection related to cataract surgery is endophthalmitis. Endophthalmitis is a result of microorganisms entering the eye, either during the surgical procedure or before surgical incisions have healed completely. The risk of infection can be reduced in several ways. Pre-operatively, reducing the bacteria on the cornea and ocular adnexa can be helpful. During surgery, appropriate technique can reduce the potential for ingress. Post-operatively, prophylactic antibiotics can eliminate organisms once they have entered the eye. Topical drops, intracameral antibiotics and subconjunctival injections are typical options in current use, usually selected on the basis of spectrum of coverage, cost, efficacy and/or expected side effects.

With regard to inflammation, one of the most common post-operative responses is cystoid macular edema (CME). Steroids and non-steroidal anti-inflammatory drugs (NSAIDs) appear effective in reducing the incidence of CME, with NSAIDs posing a lower risk for IOP spikes and showing greater efficacy some studies.

While there is documented evidence of the utility of prophylactic post-operative treatment for pain and infection, patient compliance remains a significant concern. The regimen is often complex, with multiple drops several times per day. Inability to instill the drops, forgetfulness and a lack of appreciation for the importance of compliance can all be contributing factors.

There are several new options to try to address the potential issues related to poor patient compliance. One is referred to as "dropless" cataract surgery, which involves injection of a multi-drug compound into the eye at time of cataract surgery; one such compound includes triamcinolone acetonide, moxifloxacin hydrochloride and vancomycin (TriMoxiVanc). Another alternative is to reduce the burden of the pharmaceutical regimen using a compounded topical medication; this is termed "less drops" cataract surgery. An option in this regard is a topical formulation of prednisolone acetate, moxifloxacin hydrochloride and ketorolac tromethamine (PredMoxiKetorolac), given for one week post-operatively followed by a topical formulation of prednisolone acetate and ketorolac tromethamine (PredKeterolac) given for weeks 2 to 4 after surgery.

The purpose of this study is to evaluate the differences in performance between the dropless and less-drops pharmaceutical regimens after cataract surgery.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 25 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Dropless™ vs. Less Drops™ Pharmaceutical Regimens After Cataract Surgery
Study Start Date : September 2015
Actual Primary Completion Date : April 2016
Actual Study Completion Date : April 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cataract

Arm Intervention/treatment
Active Comparator: Imprimis Dropless
TriMoxiVanc 0.2cc intravitreal one time
Drug: Imprimis Dropless
Tri-Moxi-Vanc transzonular intravitreal injection

Active Comparator: Imprimis Less Drops
Pred Moxi, 1 drop tid for 1 week then, PredKeterolac bid for 2-4 weeks.
Drug: Imprimis Less Drops
Pred-Moxi-Ketorolac and Pred-Ketorolac topical instillation qd postoperatively

Primary Outcome Measures :
  1. The change in intraocular pressure (IOP) from baseline [ Time Frame: To end of study (1 month postop) ]
    Based on Goldmann tonometry

Secondary Outcome Measures :
  1. Change in corneal thickness [ Time Frame: To end of study (1 month postop) ]
    Based on corneal pachymetry

  2. Slit lamp (cornea exam) [ Time Frame: To end of study (1 month postop) ]

Other Outcome Measures:
  1. Subject reporting no eye pain [ Time Frame: To end of study (1 month postop) ]
    "0"( on the eye pain/discomfort scale)

  2. Change from baseline eye pain/discomfort [ Time Frame: To end of study (1 month postop) ]
    eye pain/discomfort scale

  3. The proportion of subjects reporting no visual symptoms ("0" ) [ Time Frame: To end of study (1 month postop) ]
    visual symptom scale

  4. The change from baseline in visual symptoms [ Time Frame: To end of study (1 month postop) ]
    visual symptom scale

  5. The change from baseline in central corneal thickness measurements [ Time Frame: To end of study (1 month postop) ]
    corneal pachymetry

  6. The change from baseline in macular thickness measurements [ Time Frame: To end of study (1 month postop) ]
    based on optical coherence tomography (OCT) measurement

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Ocular criteria must be met in both eyes.
  • Subject is undergoing bilateral cataract extraction or refractive lens exchange with intraocular lens implantation.
  • Gender: Males and Females.
  • Age: 21 or older.
  • Willing and able to provide written informed consent for participation in the study.
  • Willing and able to comply with scheduled visits and other study procedures.
  • Willing and able to administer eye drops and record the times the drops were instilled.
  • Scheduled to undergo standard cataract surgery or refractive lens exchange with topical anesthesia in both eyes within 6-15 days of each other.
  • Potential postoperative best-corrected visual acuity of 20/30 or better.

Exclusion Criteria:

  • If any of the following exclusion criteria are applicable to the subject or either eye, the subject should not be enrolled in the study.
  • Severe preoperative ocular pathology: amblyopia, rubella cataract, proliferative diabetic retinopathy, shallow anterior chamber, macular edema, aniridia or iris atrophy, uveitis, history of iritis, iris neovascularization, medically uncontrolled glaucoma, microphthalmos or macrophthalmos, optic nerve atrophy, macular degeneration (with anticipated best postoperative visual acuity less than 20/30), advanced glaucomatous damage, etc.
  • Presence of epiretinal membrane.
  • Uncontrolled diabetes.
  • Use of any systemic or topical drug known to interfere with visual performance.
  • Contact lens use during the active treatment portion of the trial.
  • Any concurrent infectious/non-infectious conjunctivitis, keratitis or uveitis.
  • History of chronic intraocular inflammation.
  • History of retinal detachment.
  • Pseudoexfoliation syndrome or any other condition that has the potential to weaken the zonules.
  • Previous refractive surgery.
  • Anesthesia other than topical, oral or intravenous anesthesia (i.e. retrobulbar, general, etc).
  • Any clinically significant, serious or severe medical or psychiatric condition that may increase the risk associated with study participation or may interfere with the interpretation of study results.
  • Participation in (or current participation) any investigational drug or device trial within the previous 30 days prior to the start date of this trial.
  • Intraocular conventional surgery within the past three months or intraocular laser surgery within one month.

The principal investigator reserves the right to declare a patient ineligible or non-evaluable based on medical evidence that indicates they are unsuitable for the trial.

Exclusion Criteria during surgery:

If any of the following exclusion criteria are applicable to the study eye, the subject should not continue in the study.

  • If full dose (0.2 cc) is not delivered into the vitreous through the zonules as evaluated by surgeon's direct visualization of the material in the posterior chamber with lack of material in the anterior chamber and an empty syringe.
  • Significant vitreous loss.
  • Significant anterior chamber hyphema.
  • Uncontrollable intraocular pressure.
  • Zonular or capsular rupture.
  • Bag-sulcus, sulcus-sulcus or unknown placement of the haptics.
  • Suturing of incision required at time of surgery.
  • Intraocular lens tilt or decentration
  • Peri-bulbar or retro-bulbar block required during surgery.
  • Other procedure, such as pupil stretch, expanders, iris hooks during surgery.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02819908

Layout table for location information
United States, Florida
Eye Center of North Florida
Panama city, Florida, United States, 32409
Sponsors and Collaborators
Eye Center of North Florida
Layout table for investigator information
Principal Investigator: Bret L Fisher, MD Eye Center of North Florida

Layout table for additonal information
Responsible Party: Bret L. Fisher, M.D., Principal Investigator, Eye Center of North Florida Identifier: NCT02819908     History of Changes
Other Study ID Numbers: BF-2015-011
First Posted: June 30, 2016    Key Record Dates
Last Update Posted: June 30, 2016
Last Verified: June 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Capsule Opacification
Pathologic Processes
Lens Diseases
Eye Diseases